Stock search

Ticker or company name

Compare stocks

Market: US

  • GILDGilead Sciences
  • REGNRegeneron Pharmaceuticals
  • VRTXVertex Pharmaceuticals

Add stock

Ticker or company

Summary

GILD
Gilead Sciences
$167,58Down −0,30%
Year: Up +34%
25/100Ratio would not consider buying
Open stock page
REGN
Regeneron Pharmaceuticals
$952,40Down −0,32%
Year: Up +37%
67/100Ratio would watch
Open stock page
VRTX
Vertex Pharmaceuticals
$537,79Down −0,15%
Year: Up +24%
72/100Best scoreRatio would consider buying
Open stock page

Verdict

VRTX has the best score (72). REGN grows revenue the fastest. REGN is the cheapest by forward P/E. REGN has the lowest debt load. VRTX has the highest net margin. GILD has 5 of 10 checks in the red zone.

Verdict by our methodology based on current metrics. Not an investment recommendation.

Traffic light — 10 checks

CheckGILD1 ✓ 2 — 5 ✕REGN5 ✓ 2 — 2 ✕VRTX5 ✓ 3 — 1 ✕
P/E vs its history—20,533,7
P/E vs industry—20,533,7
Forward P/En/a20,913,827,2
Revenue growth, YoY+6,5%+18,6%+10,5%
EPS growth, YoY—+8,3%+9,3%
Net margin−12,5%28,5%30,7%
Net debt / EBITDA—−1,4−0,6
Free cash flow$13,8 bn$3,83 bn$3,20 bn
Share count over a year−0,2%−1,5%−0,9%
Cash runwayn/anot neededn/anot neededn/anot needed

Metrics

Best WorstNo mark — in between

Metric · betterGILDTTMREGNTTMVRTXTTMIndustry medianTTM
P/E TTM ↓n/aBest: 20,5Worst: 33,742,1
Forward P/E ↓20,9Best: 13,8Worst: 27,218,7
PEG ↓n/aBest: 1,2Worst: 3,04,1
P/S TTM ↓6,7Best: 5,8Worst: 10,36,6
EV/EBITDA ↓18,8Best: 18,2Worst: 29,628,2
P/FCF ↓Best: 15,127,2Worst: 41,926,0

Price, %

  • GILDn/a
  • REGNn/a
  • VRTXn/a

Returns

Best WorstNo mark — in between

PeriodGILDREGNVRTX
1 yearn/an/an/a
3 yearsn/an/an/a
5 yearsn/an/an/a
All timen/an/an/a

“Per year” is the average annual return: 90% growth over 3 years is 23,9% per year, not 30%. “All time” starts at the IPO, so only “per year” compares fairly. Prices adjusted for splits, dividends reinvested.

Analysts and insiders

Best WorstNo mark — in between

GILDREGNVRTX
Share of “buy”Best: 83%Worst: 72%82%
Beat the forecastBest: 4 of 4Best: 4 of 4Worst: 1 of 4
Average “surprise”+6,9%Best: +16,8%Worst: −1,5%
Insiders over 12 monthssales $102 msales $57,9 msales $129 m

Details are on each stock page.